Table of Contents
Overview
New York, NY – July 24, 2025 – The Global Point of Care Glucose Testing Market size is expected to be worth around US$ 6.3 Billion by 2033, from US$ 3.9 Billion in 2023, growing at a CAGR of 4.9% during the forecast period from 2024 to 2033.
The Point of Care (POC) Glucose Testing Market is witnessing strong growth, driven by the global rise in diabetes cases and the increasing need for rapid, on-site diagnostic solutions. Point of care glucose testing allows healthcare providers to measure blood glucose levels quickly and accurately at or near the site of patient care, enabling timely clinical decisions and improved patient management.
This market is expanding due to the shift toward decentralized healthcare, especially in emergency rooms, intensive care units, outpatient clinics, and home care environments. The use of portable and user-friendly glucose meters has enhanced the speed and efficiency of blood sugar monitoring, supporting better glycemic control in both type 1 and type 2 diabetes patients.
Growth is further supported by advancements in sensor technologies, wireless connectivity, and integration with digital health platforms. These innovations enable automatic data recording, trend tracking, and remote monitoring, improving care coordination between patients and providers.
North America continues to lead the market due to high diabetes awareness, adoption of modern healthcare technologies, and strong institutional support. Meanwhile, regions such as Asia-Pacific are experiencing increased uptake due to improved healthcare access, growing health literacy, and government initiatives aimed at early diagnosis and chronic disease management.
Key Takeaways
- The Point of Care Glucose Testing Marketis expected to expand from US$ 3.9 billion in 2023to approximately US$ 6.3 billion by 2033, growing at a CAGR of 4.9% over the forecast period.
- Among product types, Test Strips & Lancetsheld the largest share in 2023, contributing to over 52.1% of the total market.
- Based on application, Type-2 Diabetesemerged as the dominant segment in 2023, accounting for 63.5% of the market share.
- North Americaled the global market in 2023, capturing 41.4% of the total share, with a regional market value of approximately US$ 0.4 billion.
Segmentation Analysis
- Product Type Analysis: In 2023, the Test Strips & Lancets segment led the Point of Care Glucose Testing Market, accounting for over 52.1% of the product type share. Their dominance is attributed to frequent use in daily diabetes management due to ease of use, quick results, and affordability. These tools are essential in both clinical and home settings. While glucose meters also hold value, their usage is comparatively lower. Test strips and lancets remain the cornerstone of efficient and accessible glucose monitoring.
- Application Analysis: The Type-2 Diabetes segment held the largest share in 2023, exceeding 63.5% of the application category. This dominance reflects the high global prevalence of Type-2 Diabetes, particularly among adults. Point of care testing plays a vital role in enabling quick, on-the-spot monitoring, aiding better glycemic control and treatment decisions. Its importance continues to grow with the shift toward patient-centered care and disease self-management, reinforcing the segment’s strong position in the market.
- End User Analysis: In 2023, Hospitals & Clinics dominated the end user segment, capturing over 45.9% market share. This leadership is driven by the need for rapid test results to support timely clinical decisions. Simultaneously, Home Care Settings are gaining traction due to the growing number of individuals self-managing diabetes. Enhanced device usability and accuracy have supported this trend. Additionally, adoption is rising in remote clinics and long-term care facilities, expanding the reach of point of care glucose testing.
Market Segments
By Product Type
- Glucose Meters
- Test Strips & Lancets
- Others
By Application
- Type-1 Diabetes
- Type-2 Diabetes
By End User
- Hospitals and Clinics
- Home Care Settings
- Others
Regional Analysis
In 2023, North America maintained a leading position in the global Point of Care Glucose Testing Market, capturing over 41.4% of the total share, with a market value of approximately US$ 0.4 billion. This dominance is primarily attributed to the region’s high diabetes prevalence, which has created a sustained need for accessible and reliable glucose monitoring solutions.
The presence of advanced healthcare infrastructure has facilitated the rapid adoption of point of care technologies across hospitals, clinics, and home care environments. Ongoing investments from both public and private sectors continue to support innovation and improve the availability of diagnostic tools, reinforcing market growth.
Rising awareness of diabetes management and preventive care has led to greater consumer engagement and adoption of self-monitoring practices. Supportive regulatory frameworks also contribute to market expansion by ensuring that devices meet high standards for safety and performance.
Moreover, North America is at the forefront of integrating digital technologies into medical devices. Innovations such as smartphone connectivity and cloud-based monitoring enhance the usability and appeal of point of care glucose testing among tech-savvy users. As healthcare systems across the region continue to evolve, North America is expected to retain its dominant position in the global market.
Emerging Trends
- Over the counter continuous monitoring for non insulin users: The first integrated continuous glucose monitor (CGM) intended for adults who do not use insulin was cleared for marketing by the U.S. Food and Drug Administration in 2023. This device enables users aged 18 and older to track glucose levels continuously without a prescription, reflecting a shift toward broader consumer access and proactive health management.
- Expanded quality and safety guidelines in clinical settings: Point of care glucose meters have been targeted by updated infection control recommendations. In healthcare and group settings, use of single use, auto disabling fingerstick devices has been emphasized to reduce cross contamination risk. These precautions are now routinely recommended for long term care facilities and hospitals.
- Enhanced quality management practices: Greater attention is being paid to formal quality management systems for POC glucose testing. A 2024 study of institutional practices highlighted the need for standardized procedures before, during, and after testing to ensure consistent accuracy and patient safety.
- Broader use beyond hospital wards: Deployment of point of care glucose testing has been extended into non acute settings such as long term care and community health programs. These expansions are supported by practical guidelines that facilitate training of non laboratory staff and simplify device operation at the bedside.
Use Cases
- Inpatient glycemic management: In hospitalized patients with diabetes or undergoing hyperglycemia related therapies, POC blood glucose tests are recommended every 4–6 hours. This frequent testing enables rapid treatment adjustments in response to fluctuating blood sugar levels, reducing risks of hypo or hyperglycemia.
- Home self monitoring: Adults managing diabetes at home are advised to check blood glucose regularly to detect patterns and guide lifestyle adjustments. Over half (52%) of U.S. adults reported having had a glucose test within the past three years, indicating widespread adoption of self testing practices.
- Continuous monitoring without prescription: The OTC CGM system cleared by the FDA is used by adults aged 18 and over who manage diabetes with oral medications or wish to understand how diet and exercise affect their blood sugar. Continuous readings (every few minutes) support more precise adjustments to daily routines and therapies.
- Point of care in long term care facilities: Single use, auto disabling glucose meters have been endorsed by CDC guidelines for long term care settings. Their adoption has enabled nursing staff to conduct on site testing for large resident populations while minimizing infection risk and ensuring device traceability.
Conclusion
The Point of Care Glucose Testing Market is witnessing steady expansion, driven by the global diabetes burden, technological advancements, and increasing emphasis on patient-centered care. Dominated by test strips and lancets, the market continues to benefit from their accessibility, affordability, and clinical reliability. Type-2 diabetes remains the leading application segment, while hospitals, clinics, and home care settings contribute significantly to end-user demand.
North America leads the global landscape, supported by robust infrastructure and rising awareness. With emerging trends such as OTC CGMs and enhanced quality standards, the market is expected to grow further, ensuring improved diabetes management across diverse healthcare settings.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
